Argenx, a global immunology company dedicated to improving the lives of individuals with severe autoimmune diseases, has announced that it will be hosting a conference call and audio webcast on May 9, 2024, at 2:30 PM CET. The webcast can be accessed on the Investors section of the argenx website. A replay of the webcast will be available for approximately one year after the presentation.
Participants from various countries can dial in using the numbers provided, with an access code required to join the call. It is recommended to dial in 15 minutes before the scheduled start time to ensure a smooth connection.
Argenx specializes in translating immunology breakthroughs into novel antibody-based medicines through its Immunology Innovation Program (IIP). The company has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker in several countries. Currently, argenx is evaluating efgartigimod in multiple serious autoimmune diseases and progressing experimental medicines within its therapeutic franchises.
For more information about argenx, including its portfolio of medicines and ongoing research, visit their website and follow their social media accounts. For media inquiries, please contact Ben Petok, and for investor relations, contact Alexandra Roy for the US or Lynn Elton for the EU.
